DEFR14A: Black Hawk Acquisition Seeks Shareholder Approval to Extend Business Combination Deadline Amidst Vesicor Merger Efforts

Black Hawk Acquisition Corporation is seeking shareholder approval to extend its business combination deadline by 18 months to December 22, 2026, to facilitate the completion of its proposed merger with Vesicor Therapeutics, Inc.

Summary

• Black Hawk Acquisition Corporation (a SPAC) is holding an Extraordinary General Meeting on June 20, 2025, to vote on extending its business combination deadline.
• The company proposes to amend its charter and trust agreement to extend the period for consummating a business combination from the current June 22, 2025, Termination Date to December 22, 2026, allowing for up to 18 additional one-month extensions.
• Each one-month extension would require a deposit into the trust account of $0.033 multiplied by the number of outstanding public shares, up to $55,000 per extension.
• A definitive business combination agreement with Vesicor Therapeutics, Inc. was entered into on April 26, 2025, but the company states it may not be able to complete it by the current deadline.
• Public shareholders have the right to redeem their shares for cash, regardless of their vote on the extension, with an anticipated per-share redemption price of approximately $10.63 based on the Trust Account balance of $73,379,601.56 as of June 2, 2025.
• The deadline for shareholders to elect to redeem their public shares has been changed to 5:00 p.m. Eastern Time on June 17, 2025.
• If the extension proposals are not approved and a business combination is not consummated by the current deadline, the company will liquidate, redeeming public shares and rendering rights worthless.

Sentiment

Score: 4

Explanation: The sentiment is cautiously negative. While the company has a definitive merger agreement, the need for an extension indicates a delay or challenge in closing the deal. This introduces uncertainty and the risk of liquidation if the extension is not approved or if the deal still fails to close within the extended period. The potential for significant redemptions and Nasdaq delisting also weighs on the sentiment.

Positives

• The proposed extension provides Black Hawk Acquisition Corporation with additional time, up to December 22, 2026, to complete its business combination with Vesicor Therapeutics, Inc., or find an alternative target.
• Shareholders who wish to continue with the company's efforts to find a business combination are given the opportunity to do so by voting for the extension.
• Public shareholders retain the right to redeem their shares for a pro-rata portion of the trust account, offering a liquidity option at an anticipated price of approximately $10.63 per share, which is slightly above the June 2, 2025 closing price of $10.60.

Negatives

• The need for an extension indicates that the company has not been able to consummate its business combination by the original deadline, suggesting potential challenges or delays in the merger process.
• Significant redemptions by public shareholders could reduce the amount of cash available in the Trust Account, potentially leaving insufficient funds to consummate a business combination on commercially acceptable terms or at all.
• If redemptions are substantial, the company risks delisting from Nasdaq due to failure to meet continued listing requirements (e.g., minimum public shareholders, publicly held shares, or market value of listed securities).
• The sponsor is not obligated to fund the trust account for extensions, introducing uncertainty regarding the company's ability to secure the necessary funds for each one-month extension.
• If the extension proposals are not approved, the company will be forced to liquidate, resulting in the expiration of public rights and the loss of potential investment appreciation in a successor operating business.

Risks

• There is no assurance that the Extension Amendment will enable the company to complete a business combination, as many factors are beyond its control.
• Even if the extension and business combination are approved, redemptions could leave insufficient cash to consummate a business combination.
• The ability of public shareholders to exercise redemption rights for a large number of shares may adversely affect the liquidity of the company's securities.
• Nasdaq may delist the company's securities if shareholder redemptions cause non-compliance with continued listing requirements, leading to reduced liquidity and trading activity.
• Changes in laws or regulations, or their interpretation (e.g., SEC SPAC Rules, Investment Company Act), may adversely affect the company's ability to complete an initial business combination.
• The company may be deemed an unregistered investment company, which would severely restrict its activities and could force liquidation.
• The Committee on Foreign Investment in the U.S. (CFIUS) or other regulatory agencies may modify, delay, or prevent the business combination.
• Trading in the company's securities may be prohibited under the Holding Foreign Companies Accountable Act if the PCAOB cannot inspect or fully investigate its auditor, leading to delisting.

Future Outlook

The company's future outlook is contingent on securing shareholder approval for the extension of its business combination deadline to December 22, 2026. If approved, Black Hawk will continue efforts to consummate its definitive agreement with Vesicor Therapeutics, Inc. or pursue an alternative business combination. If the extension is not approved, the company will be forced to liquidate and redeem its public shares.

Management Comments

• "You are cordially invited to attend Black Hawk Acquisition Corporation’s Extraordinary General Meeting of Shareholders..."
• "Thank you for your continued support of and interest in Black Hawk Acquisition Corporation."
• "YOUR VOTE IS IMPORTANT TO ASSURE YOUR REPRESENTATION AT THE EXTRAORDINARY GENERAL MEETING WHETHER OR NOT YOU ATTEND VIA TELECONFERENCE, PLEASE CAST YOUR VOTE AS INSTRUCTED IN THE NOTICE OF INTERNET AVAILABILITY OF PROXY MATERIALS AS PROMPTLY AS POSSIBLE."
• The Board unanimously recommends that the company's shareholders vote FOR the Extension Amendment Proposal, the Trust Agreement Amendment Proposal, and the Adjournment Proposal.

Industry Context

This filing is typical for a Special Purpose Acquisition Company (SPAC) that is approaching its initial business combination deadline and requires more time to complete a de-SPAC transaction. The need for an extension, despite having a definitive agreement, highlights the complexities and potential delays inherent in SPAC mergers, often due to regulatory approvals, due diligence, or financing conditions. The document also references broader industry trends such as increased SEC scrutiny on SPACs (SPAC Rules) and potential delisting risks (HFCAA), which are significant considerations for all SPACs.

Comparison to Industry Standards

• NA

Corporate Governance

Related Party Transactions

• Black Hawk Management LLC (the Sponsor) may deposit funds into the Trust Account for extensions, receiving a non-interest bearing, unsecured promissory note in return. The Sponsor is not obligated to fund these extensions.

Stakeholder Impact

• **Shareholders**: Face a decision on whether to redeem their shares for cash now or hold them in anticipation of a future business combination. Potential for dilution if many shareholders redeem, increasing the percentage interest of remaining shareholders and the sponsor. Risk of losing investment if the company liquidates.
• **Management/Sponsor**: Gains additional time to complete the business combination, but also bears the responsibility and potential cost of funding extensions. Their founder shares and private shares would expire worthless in a liquidation.
• **Vesicor Therapeutics, Inc.**: The target company benefits from the extension, as it provides more time for the merger to close, but also faces prolonged uncertainty regarding the completion of the transaction.

Next Steps

• Hold the Extraordinary General Meeting of Shareholders on June 20, 2025, to vote on the extension proposals.
• If approved, file the Extension Amendment with the Cayman Islands Registrar of Companies.
• Continue efforts to consummate the business combination with Vesicor Therapeutics, Inc. or pursue an alternative target by the extended deadline of December 22, 2026.
• If the extension is not approved and a business combination is not completed by June 22, 2025, the company will cease operations and liquidate.

Key Dates

Recommendation

Keywords

SPAC, Special Purpose Acquisition Company, Business Combination, Extension, Proxy Statement, Shareholder Meeting, Redemption Rights, Vesicor Therapeutics, Trust Account, Nasdaq Delisting, SEC Filings, Corporate Governance